Physician profile
Drew Dill
NPI 1578723276
$7,654.98
in general payments reported to CMS, 2019-2025
53 companies · $1,483 in 2025
The $1,483 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,525 · 2020: $222 · 2021: $109 · 2022: $1,404 · 2023: $1,479 · 2024: $1,432 · 2025: $1,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,293 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,293.21 |
| Education | $100.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $587.56 | 2019-2025 | |
| Celgene Corporation | $521.35 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Glaxosmithkline, LLC. | $491.46 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $490.04 | 2019-2025 | Opdivo, Opdualag |
| Gilead Sciences, INC. | $487.51 | 2021-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $396.19 | 2021-2025 | Enhertu, Lynparza |
| Janssen Biotech, INC. | $376.89 | 2019-2025 | Darzalex, Imbruvica, Akeega |
| Lilly USA, LLC | $360.69 | 2019-2025 | Verzenio, Jaypirca |
| Abbvie INC. | $292.83 | 2019-2025 | Venclexta |
| Eisai INC. | $291.70 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $274.77 | 2019-2024 | Reblozyl, Lynparza, Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $273.94 | 2019-2025 | Ninlaro |
| Rigel Pharmaceuticals, INC. | $256.08 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Incyte Corporation | $232.98 | 2019-2023 | Jakafi |
| Puma Biotechnology, INC. | $221.43 | 2019-2023 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $181.22 | 2019-2023 | |
| Daiichi Sankyo INC. | $177.41 | 2022-2025 | Enhertu, Datroway |
| Tempus Ai, INC | $172.87 | 2024-2025 | Xt Cdx |
| Dendreon Pharmaceuticals LLC | $152.80 | 2019-2020 | |
| Genzyme Corporation | $127.13 | 2022-2025 | |
| Servier Pharmaceuticals LLC | $97.19 | 2022-2024 | |
| Springworks Therapeutics, INC. | $90.45 | 2024-2025 | Ogsiveo |
| Exelixis INC. | $83.62 | 2019-2023 | Cabometyx |
| Amgen INC. | $75.51 | 2019-2023 | Kyprolis, Blincyto, Nplate |
| Genentech USA, INC. | $61.62 | 2022 | |
| Jazz Pharmaceuticals INC. | $61.20 | 2022-2025 | |
| Novo Nordisk INC | $59.21 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $56.20 | 2022-2023 | Imbruvica |
| Beigene USA, INC. | $55.57 | 2022-2024 | Brukinsa |
| Array Biopharma INC | $46.96 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Portola Pharmaceuticals, LLC | $46.36 | 2019 | |
| Biocompatibles, INC. | $41.80 | 2019 | |
| Alexion Pharmaceuticals, INC. | $39.99 | 2022-2023 | Ultomiris |
| Janssen Pharmaceuticals, INC | $39.56 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $39.22 | 2023-2024 | Xpovio |
| Sobi, INC | $37.38 | 2023-2024 | |
| Emd Serono, INC. | $34.75 | 2022-2023 | Tepmetko |
| Sumitomo Pharma America, INC. | $29.33 | 2023 | Orgovyx |
| Astellas Pharma US INC | $29.25 | 2025 | Vyloy, Padcev |
| Kite Pharma, INC. | $28.95 | 2023-2024 | Yescarta |
| Secura Bio, INC. | $27.77 | 2022 | |
| Genmab U.S., INC. | $22.54 | 2023 | Epkinly |
| Novocure INC. | $21.25 | 2025 | Optune Lua (Novottf-200t) |
| Bayer Healthcare Pharmaceuticals INC. | $19.76 | 2022 | |
| Recordati_rare_diseases_inc. | $19.31 | 2025 | Enjaymo |
| Regeneron Healthcare Solutions, INC. | $19.14 | 2024 | Libtayo |
| Mirati Therapeutics, INC. | $17.78 | 2023 | Krazati |
| Seagen INC. | $15.44 | 2022 | |
| Tactile Systems Technology INC | $15.32 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.01 | 2019 | |
| Boston Scientific Corporation | $14.78 | 2020 | |
| Kyowa Kirin, INC. | $13.68 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Dill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.